PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients

Cancers

Pier Luigi Zinzani¹  Lisa Argnani¹  Chiara Tarantelli²  Francesco Bertoni² 

[1] IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy;Institute of Oncology Research, Faculty of Biomedical Sciences, USI, 6500 Bellinzona, Switzerland;

关键词: lymphoma;    PI3K inhibitors;    T-cells;    B-cells;    macrophages;    chemokine;   

DOI  :  10.3390/cancers13215535

来源: DOAJ

【 摘 要 】

The development of small molecules able to block specific or multiple isoforms of phosphoinositide 3-kinases (PI3K) has already been an active field of research for many years in the cancer field. PI3Kδ inhibitors are among the targeted agents most extensively studied for the treatment of lymphoma patients and PI3Kδ inhibitors are already approved by regulatory agencies. More recently, it became clear that the anti-tumor activity of PI3K inhibitors might not be due only to a direct effect on the cancer cells but it can also be mediated via inhibition of the kinases in non-neoplastic cells present in the tumor microenvironment. T-cells represent an important component of the tumor microenvironment and they comprise different subpopulations that can have both anti- and pro-tumor effects. In this review article, we discuss the effects that PI3Kδ inhibitors exert on the immune system with a particular focus on the T-cell compartment.

【 授权许可】

Unknown